- Home
- STTK vs FENC Comparison
STTK vs FENC Comparison
Compare STTK & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STTK | FENC |
|---|---|---|
| Founded | 2016 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.9M | 263.3M |
| IPO Year | 2020 | 2001 |
Fundamental Metrics
Financial Performance| Metric | STTK | FENC |
|---|---|---|
| Price | $4.01 | $7.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $6.20 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 893.1K | 116.2K |
| Earning Date | 11-06-2025 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,000,000.00 | ★ $38,790,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $70.78 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.69 | $4.68 |
| 52 Week High | $4.89 | $9.92 |
Technical Indicators
Market Signals| Indicator | STTK | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 49.25 | 55.73 |
| Support Level | $3.92 | $7.40 |
| Resistance Level | $4.46 | $7.95 |
| Average True Range (ATR) | 0.35 | 0.28 |
| MACD | -0.12 | 0.03 |
| Stochastic Oscillator | 20.64 | 71.02 |
Price Performance
Historical ComparisonAbout STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.